Dr. Amber Afzal, MD

Dr. Afzal practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Afzal's NPI, 1831539808, was assigned on July 4, 2013. Dr. Afzal holds Missouri license 2016023328.

Dr. Afzal's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Afzal also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Afzal's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Afzal is also affiliated with Christian Hospital. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Afzal to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Afzal practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Afzal's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Afzal is licensed in Missouri.

CMS data shows 330 Medicare services from Dr. Afzal across 9 procedure codes in 2024, for 222 Medicare patients. Medicare paid $21,653 for them.

CMS counts 222 Medicare patients who saw Dr. Afzal in 2024. The largest group is 65 to 74, with 84 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 24% are also on Medicaid. Their average risk score is 2.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Afzal's median patient age at 70, with 56% women.

In 2024, Dr. Afzal wrote 720 Medicare Part D claims for 106 patients. 50% of them were for generic drugs. CMS names the drug for 642 of them, across 16 drugs with 11 or more claims each, at $2,472,887 in total drug cost. In 2023, CMS named 387 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Afzal for performance year 2024, reported as part of a group. Dr. Afzal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Afzal as offering telehealth.

Dmand AI links 16 papers to Dr. Afzal, published from 2019 to 2025. 2025 was the busiest year, with 4. The most frequent topics are Anticoagulants, Hemorrhage and Hematologic Neoplasms. Dr. Afzal has published most often in Res Pract Thromb Haemost. Dr. Afzal's most frequent co-authors are Kristen Marie Sanfilippo, MD, Brian F. Gage, MD and Martin William Schoen, MD.

Dmand AI links Dr. Afzal to 2 clinical trials. Conditions studied include Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia and Cytopenia.

CMS Open Payments shows 4 general payments to Dr. Afzal from 3 drug and device companies from 2019 to 2025. Education make up the largest share, 80% of the total. Incyte Corporation paid the most, $72.